Further support for insulin degludec to reduce nocturnal hypoglycemia risk in type 1 diabetes
medwireNews: Use of insulin degludec is associated with a reduced risk for recurrent nocturnal hypoglycemia as measured by hourly plasma glucose among adults with type 1 diabetes, suggest findings from the overnight substudy of the HypoDeg trial.
The main findings from the phase 4 crossover trial, reported previously by medwireNews, showed that participants with at least one episode of severe nocturnal hypoglycemia in the past 2 years had significantly lower rates of symptomatic nocturnal hypoglycemia when using insulin degludec versus glargine U100 as their basal insulin.
The overnight substudy, reported by Julie Brøsen (Nordsjællands Hospital, Hillerød, Denmark) at the virtual ADA 81st Scientific Sessions, included 51 of the 149 HypoDeg participants who had hourly plasma glucose measurements taken during 196 nights.
Brøsen said that the proportion of nights with hypoglycemic episodes was lower during treatment with degludec than with glargine, at 33% and 67%, respectively.
The team then calculated the probability of experiencing a hypoglycemia-free night at level 1 (≤70 mg/dL [3.9 mmol/L]) and level 2 (<54 mg/dL [3.0 mmol/L]), finding that degludec was associated with a significant 54% reduced risk for level 1 and a significant 64% lower risk for level 2 hypoglycemia relative to glargine U100.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group